To assess whether the sensitivity to ICB was dependent on theanatomic site of tumour growth, as previously shown (29), we also treated orthotopic KPAR lung tumours withanti-PD-1, anti-CTLA-4 or a combination of both. The gene discussed is CTLA4; the disease is neoplasm.